Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Axitinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Axitinib. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-003436-13 Sponsor Protocol Number: 105RC101 Start Date*: 2016-05-24
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-004562-16 Sponsor Protocol Number: ICR-CTSU/2011/10033 Start Date*: 2012-05-15
    Sponsor Name:Institute of Cancer Research [...]
    1. Institute of Cancer Research
    2. The Royal Marsden Hospital NHS Foundation Trust
    Full Title: A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-002598-49 Sponsor Protocol Number: CRO1885 Start Date*: 2012-04-23
    Sponsor Name:Imperial College Joint Research Office
    Full Title: The AXitinib MicroBubble UltraSound in metastatic Colorectal cancer trial
    Medical condition: Third line colorectal liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004098-23 Sponsor Protocol Number: Tide-A Start Date*: 2020-06-18
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001150-35 Sponsor Protocol Number: AxIn Start Date*: 2022-11-10
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study).
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002429-20 Sponsor Protocol Number: B9991003 Start Date*: 2016-08-05
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE FIRST-LINE TRE...
    Medical condition: Advanced renal cell carcinoma (aRCC).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10023405 Kidney cancer stage IV LLT
    21.0 100000004864 10023404 Kidney cancer stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Ongoing) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) AT (Completed) DK (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006007-23 Sponsor Protocol Number: STH15195 Start Date*: 2009-12-15
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
    Medical condition: Soft tissue sarcoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001793-26 Sponsor Protocol Number: 3590 Start Date*: 2011-10-31
    Sponsor Name:Royal Marsden Hospital
    Full Title: A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma
    Medical condition: Advanced BRAF mutant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000588-17 Sponsor Protocol Number: MK-3475-426 Start Date*: 2016-12-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally A...
    Medical condition: Advanced Kidney Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2011-000900-16 Sponsor Protocol Number: UZB-BN-11-001 Start Date*: 2011-05-05
    Sponsor Name:UZ BRUSSEL
    Full Title: AA randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma
    Medical condition: • Patients with recurrent central nervous system glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021590-37 Sponsor Protocol Number: A4061058 Start Date*: 2011-01-03
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA
    Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI...
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005596-40 Sponsor Protocol Number: SFT-AX2014 Start Date*: 2014-03-14
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor
    Medical condition: Advanced solitary fibrous tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000399-28 Sponsor Protocol Number: AIO-NZK-0115/ass. Start Date*: 2016-12-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitin...
    Medical condition: advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006430-39 Sponsor Protocol Number: BO43936 Start Date*: 2023-03-07
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    25.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086821 Advanced renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001451-21 Sponsor Protocol Number: A4061032 Start Date*: 2008-06-18
    Sponsor Name:Pfizer Inc.,235 East 42nd Street,New York,NY 10017
    Full Title: AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) AT (Completed) FR (Completed) GB (Completed) IE (Completed) DE (Completed) IT (Completed) PL (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000619-17 Sponsor Protocol Number: NAXIVA1.0 Start Date*: 2017-08-02
    Sponsor Name:Common Services Agency (CSA)
    Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.
    Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001065-21 Sponsor Protocol Number: ET21-023 Start Date*: 2021-10-12
    Sponsor Name:CENTRE LEON BERARD
    Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)
    Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006009-85 Sponsor Protocol Number: 1 Start Date*: 2012-06-04
    Sponsor Name:VU University medical center
    Full Title: Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001550-29 Sponsor Protocol Number: AXI-IIG-02 Start Date*: 2011-08-11
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa...
    Medical condition: Patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003998-96 Sponsor Protocol Number: AXAGIST Start Date*: 2019-04-03
    Sponsor Name:Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie
    Full Title: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
    Medical condition: GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 11:44:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA